Heron Therapeutics, Inc. (HRTX) Financials
HRTX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 222.5 million | 256.5 million |
2023-09-30 | 229.2 million | 257.0 million |
2023-06-30 | 201.2 million | 240.5 million |
2023-03-31 | 220.9 million | 232.3 million |
HRTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 2.2 million | 4.3 million |
2023-09-30 | -10.0 million | 6.7 million |
2023-06-30 | -27.4 million | 13.9 million |
2023-03-31 | -25.1 million | 7.9 million |
HRTX Net Income
No data available :(
HRTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 80.4 million | - | 5.9 million |
2023-09-30 | 77.4 million | - | 6.5 million |
2023-06-30 | 33.2 million | 149.4 million | 6.7 million |
2023-03-31 | 60.0 million | 149.3 million | 7.6 million |
HRTX Shares Outstanding
HRTX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 250000 | 11.0 million | 11.3 million | 12.3 million |
2023-09-30 | 793000 | 13.6 million | 11.6 million | 13.0 million |
2023-06-30 | 278000 | 17.6 million | 15.2 million | 21.2 million |
2023-03-31 | 224000 | 13.8 million | 10.9 million | 21.2 million |
HRTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 34.2 million | 9.9 million |
2023-09-30 | 31.4 million | 18.2 million |
2023-06-30 | 31.8 million | 20.2 million |
2023-03-31 | 29.6 million | 16.9 million |
HRTX
Price: $2.55
52 week price:
Earnings Per Share: -0.80 USD
P/E Ratio: -2.99
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 4.0 million
Ebitda: -40.9 millionMarket Capitalization: 437.5 million